PhRMA's Scott LaGanga discusses the expanding influence of state policymaking on drug pricing, PBM reform, and efforts to translate policy changes into lower out-of-pocket costs for patients.
Advertisement
Advertisement
Trending on PharmExec
1
Novo Terminates Research Collaboration With Korro Bio
2
FDA Grants Accelerated Approval to Rybrevant Faspro in Head and Neck Cancer
3
The Promise of Microgravity for R&D and Manufacturing
4
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
5